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Abstract
Background: We have previously reported that induced pluripotent stem cell (iPSC)-mesenchymal stem cells
(MSCs) alleviated asthma inflammation in mice. Long noncoding RNAs (lncRNAs) were recently reported as being
involved in the immune responses. However, whether lncRNAs are associated with iPSC-MSC immunomodulation
in allergic inflammation is still unclear.
Methods: Mice were induced into an asthmatic state and received treatment consisting of iPSC-MSCs. Memory T
cells isolated from sensitized mice were challenged and co-cultured with iPSC-MSCs in vitro. Total RNA from the
lungs and separated T cells were processed with an lncRNA/mRNA microarray. A series of bioinformatics
technologies were used to screen the target lncRNAs.
Results: iPSC-MSCs significantly prevented asthma inflammation and decreased the Th2 cytokine levels. Over 1300
lncRNAs were differentially expressed after the induction of asthma, and 846 or 4176 lncRNAs were differentially
expressed with iPSC-MSC treatment in mice or in vitro, respectively. After overlapping the differentially expressed
lncRNAs produced in a similar manner in mice and in vitro, 23 lncRNAs and 96 mRNAs were selected, in which 58
protein-coding genes were predicted to be potential targets of the 23 lncRNAs. Furthermore, using a series of
bioinformatics technologies, 9 lncRNAs co-expressed with the most differentially expressed mRNAs, which were
enriched in terms of the immune response, were screened out via Pearson’s correlation coefficient with mRNAs
that were involved with inflammatory cytokines and receptors. lncRNAs MM9LINCRNAEXON12105+ and AK089315
were finally emphasized via quantitative real-time PCR validation.
Conclusions: Our results suggested that aberrant lncRNA profiles were present after asthma induction and iPSC-
MSC treatment, suggesting potential targets of allergic inflammation and iPSC-MSC-mediated immunomodulation.
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Background
Asthma has become a global public health problem that
negatively affects the quality of life of patients and
causes a substantial medical and financial burden [1]. As
an allergic airway inflammation disease, asthma is distin-
guished by a T lymphocyte imbalance and type 2 helper
T (Th2) cell preponderance, airway hyper-reactivity,
mucus hypersecretion, and reversible airway obstruc-
tions [2]. Allergy is also associated with dendritic cells
(DCs), T regulatory (Treg) cells, and group 2 innate
lymphoid cell (ILC2) dysfunction [3]. At present, a lot of
reports are related to allergy pathogenesis [4]; however,
reports about the noncoding RNA involved in allergic
airway inflammation are limited.
Long noncoding RNAs (lncRNAs) are a group of
functional RNA molecules with transcription lengths of
more than 200 nucleotides which do not encode any
protein products [5]. lncRNAs widely participate in
physiological/pathological processes and human
diseases, especially in tumorigenesis [6]. Hu et al. [7]
reported that lncRNAs were differentially expressed in T
cell development and differentiation. Moreover,
lncRNAs were also reported as regulating the differenti-
ation of DCs and the function of Treg cells [8, 9], which
participate in CD4+ T-cell development and the activa-
tion process [10]. The expression profiles of lncRNAs
were reported as being altered in eosinophilic esopha-
gitis and in the CD8+ T cells of severe asthma patients
[11, 12]. Therefore, we speculated that lncRNAs might
be involved in airway allergic inflammation.
Mesenchymal stem cells (MSCs) have shown broad
immunomodulatory properties [13, 14]. Bone marrow
(BM)-derived MSCs (BM-MSCs) were reported to have
immune regulation functions [15]. We have reported
that MSCs derived from induced pluripotent stem cells
(iPSCs), which have similar characteristics to BM-MSCs,
effectively inhibited airway allergic inflammation in mice
and significantly decreased immunoglobulin (Ig)E and
Th2 cytokine expression levels [16]. Furthermore, our
study found that iPSC-MSCs effectively improved per-
ipheral blood T lymphocyte subsets in allergic rhinitis
patients with immune imbalances [17]. However, the ef-
fects of iPSC-MSCs on lncRNAs in allergic airway in-
flammation remain to be further understood. Several
studies reported on the lncRNA profiles in MSCs but
not the targeted cells of MSCs [18]. The lncRNA expres-
sions in the tissues or cells with the immunomodulation
of MSCs were unclear. Here, we hypothesized that
lncRNAs may be associated with iPSC-MSC immuno-
modulatory properties in airway allergic inflammation.
In this study, we induced a mouse model of asthma in
which iPSC-MSCs were transplanted into the mice to
study the lncRNAs involved in the allergy and MSC im-
munomodulatory process. Moreover, an in vitro model
mimicking an allergy environment was also used. Both
in vivo and in vitro studies identified differentially
expressed lncRNAs that might be associated with the
process of airway allergy and iPSC-MSC treatment. The
identified lncRNAs were screened out using a series of
bioinformatics technologies and validated by quantitative
real-time polymerase chain reaction (qRT-PCR). Taken
together, our results provide a key foundation for
lncRNA functional studies in the fields of airway allergic
inflammation and iPSC-MSC immunomodulatory prop-
erties. This is the first study that links lncRNAs with the
effects of iPSC-MSCs in allergic airway inflammation.
Methods
Animals
Female BALB/c mice (4–6 weeks of age) were purchased
from the Guangdong Medical Laboratory Animal Centre
(Guangzhou, China). All procedures were performed
according to the protocols approved by the Sun Yat-sen
University Institutional Animal Care and Use Committee.
Preparation and culture of pluripotent stem cell-
mesenchymal stem cells
The human iPSC-MSCs used in this study were
prepared in a similar way to our previous study, titled
Effects of mesenchymal stem cells from human iPS cells
on differentiation, maturation, and function of dendritic
cells, which is under revision in Stem Cell Research &
Therapy. Similar to general MSCs, iPSC-MSCs were
positive for CD105, CD73, CD90, CD146, CD144, and
CD44, and negative for CD34, CD14, and CD45. iPSC-
MSC activities of osteogenic, chondrogenic, and adipo-
genic differentiation were confirmed. Detailed informa-
tion on iPSC-MSCs is presented in Additional file 1.
In vivo study
The mouse model of asthma was established according to
our previous description with minor modifications [16, 19].
The mice were divided into three groups (n= 15, 16, and 15
for phosphate-buffered saline (PBS)/PBS/PBS, ovalbumin
(OVA)/OVA/PBS, and OVA/OVA/iPSC-MSC, respectively).
Airway responsiveness to methacholine (Mch), asthmatic in-
flammation in the lung, and RNA microarray extraction
were analyzed. The details are presented in Additional file 1.
In vitro study
The mice (n = 8) were sensitized by OVA on day 1 and
day 7 and were sacrificed on day 14 to obtain the mem-
ory T (Tm) cells [20]. The Tm cells were stimulated with
OVA and co-cultured with iPSC-MSCs. The interleukin
(IL)-4 and IL-13 levels in the supernatant were mea-
sured. The details are presented in Additional file 1.
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lncRNA and mRNA microarrays
For the in vivo study (n = 3 for each group), total RNA
for the lncRNA and mRNA microarrays was extracted
from the lung tissues of three different groups (PBS/
PBS/PBS, OVA/OVA/PBS, and OVA/OVA/iPSC-MSC).
For the in vitro study (n = 3 for each group), total RNA
for the lncRNA and mRNA microarrays was extracted
from Tm cells that separated from the co-culture of two
different groups (Tm +OVA and Tm +OVA + iPSC-
MSC). The microarray service was provided by Arraystar
(Arraystar, Rockville, MD, USA). The extract data were
processed using the Agilent Feature Extraction Software.
Cis and trans analyses
We predicted the potential targets of differentially
expressed lncRNAs via cis and trans analyses. For the
cis-acting analysis, we located the lncRNA positions with
the RefSeq and UCSC Known Genes databases (mm10)
within 10 kb of the known genes. For trans-acting ana-
lysis, we used BLAST software for the first round of
screening (e < 1E-20) and the RNAplex software to
choose trans-acting targets. The RNAplex parameters
were set as –e-30.
Pearsons’ correlation coefficient of lncRNA-mRNA
A Pearson’s correlation coefficient between the lncRNAs
and mRNAs associated with the immune response was
constructed. A Pearson’s correlation coefficient >0.6 or
< –0.6 and p < 0.05 was considered correlative.
Gene ontology and pathway analysis
A gene ontology (GO) analysis was performed to
characterize genes and gene products in terms of the
biological process (BP), cellular component (CC), and
molecular function (MF). Fisher’s exact test was used to
find if there was overlap between the differentially
expressed list and the GO annotation list. The pathway
analysis was a functional analysis that maps genes to
KEGG pathways. This analysis was used to determine
the main pathways in which differentially expressed
mRNAs were enriched.
RNA extraction and lncRNA quantification using qRT-PCR
Aberrant lncRNAs were finally selected from the
lncRNA microarray results and were confirmed with
additional samples using qRT-PCR (n = 6, 7, and 6 for
PBS/PBS/PBS, OVA/OVA/PBS, and OVA/OVA/iPSC-
MSC, respectively). The details are presented in
Additional file 1. The primers used in the qRT-PCR are
shown in Additional file 1: Table S1.
Statistical analysis
The experimental data are expressed as the mean ±
SEM. All statistical analyses were performed with SPSS
software. For the Gaussian distribution data, one-way
analysis of variance (ANOVA) followed by post-hoc
Tukey (for equal homogeneity) or Dunnett T3 (for unequal
homogeneity) tests were used for multiple comparisons be-
tween different groups. A Kruskal–Wallis rank sum test
followed by a Mann–Whitney U test was performed for the
comparisons that utilized abnormal distribution data. p <
0.05 was considered statistically significant.
Results
Identification of targeted lncRNAs
Figure 1 summarized the systematic identification of
lncRNAs in this study. We identified the possible
lncRNAs that were involved in allergic inflammation
and the immunomodulation of iPSC-MSCs. An OVA-
induced allergy was established in both in vivo and in
vitro environments, as described in the Materials and
methods (Fig. 1a). lncRNAs and mRNAs that were dif-
ferentially expressed in vivo and in vitro were isolated
from the microarray data, respectively (Fig. 1b). After-
ward, 23 lncRNAs and 96 mRNAs that were expressed
in the same trend after the induction of asthma and with
the treatment of iPSC-MSCs, both in vivo and in vitro,
were selected (Fig. 1c). A series of bioinformatics
technologies were used to further narrow down the
allergy-specific candidate lncRNAs (Fig. 1d). Fifty-eight
potential genes were predicted as targets of the selected
23 lncRNAs; nine lncRNAs that were correlated to the
mRNAs involved in inflammation were further identified
out of the 23. Pearson’s correlation coefficient between
the 9 lncRNAs and 96 differentially expressed mRNAs
was also calculated to confirm their co-expression
relationship. To investigate the functions and pathways
associated with 9 lncRNAs, we performed GO and a
pathway analysis of both the 58 target genes and the 96
co-expressed mRNAs.
iPSC-MSCs reduced airway inflammation in mice and
decreased Th2 cytokine secretion in vitro
Similar to our previous study [16, 19], the OVA/OVA/
PBS group mice showed increased lung inflammatory in-
filtration compared to the PBS/PBS/PBS group (Fig. 2a).
Moreover, the mouse models also showed higher airway
hyperresponsiveness (AHR) levels at different Mch con-
centrations (6.25, 25, 50, and 100 mg/ml; Additional file
1: Figure S1). However, iPSC-MSC administration allevi-
ated peribronchial inflammation (hematoxylin and eosin
(H&E) staining) and decreased mucus secretion of
hyperplastic goblet cells (periodic acid-Schiff (PAS)
staining) (Fig. 2a), and significantly inhibited AHR
(Additional file 1: Figure S1). Pathological scoring (H&E
and PAS) in the OVA/OVA/iPSC-MSC group was de-
creased two- to threefold compared to the OVA/OVA/
PBS group (Fig. 2b). We also observed that iPSC-MSCs
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significantly decreased the serum IgE level and Th2
cytokine levels (IL-4, IL-5, and IL-13) in the lavage fluid
(data not shown). These results confirmed our previous
study that iPSC-MSC treatment was effective in murine
airway allergic inflammation [16].
To further identify the effects of iPSC-MSCs on Th2
responses and to identify the possible lncRNAs involved
in the immunomodulation of iPSC-MSCs from the huge
amount of microarray data, we used an in vitro model to
mimic the Th2 environment. The Tm cells were isolated
and purified from the spleen mononuclear cells of mice,
which were sensitized twice using OVA and then were
further stimulated with OVA in culture systems. We
found that both IL-4 and IL-13 (Fig. 2c), but not IL-5
with undetectable levels (data not shown), were signifi-
cantly upregulated after being stimulated by OVA com-
pared to the Tm only group (both p < 0.01; Fig. 2c).
However, the administration of iPSC-MSCs dramatically
reduced these cytokine levels (both p < 0.01; Fig. 2c),
similar to our in vivo results.
mRNA and lncRNA expression profiles in allergy and
iPSC-MSC immunomodulation
mRNA and lncRNA expression profiles were measured via
microarrays. The lncRNA microarray covered more than
24,000 lncRNAs in mice. As shown in Fig. 3, 1340 lncRNAs
were observed as differentially expressed after the induction
of airway allergic inflammation, with 666 lncRNAs upregu-
lated and 674 lncRNAs downregulated in the OVA/OVA/
PBS group compared to the PBS/PBS/PBS group. A total of
846 lncRNAs were observed to be differentially expressed
after the treatment of iPSC-MSCs, with 387 lncRNAs up-
regulated and 459 lncRNAs downregulated in the OVA/
OVA/iPSC-MSC group compared to the OVA/OVA/PBS
group. A total of 4176 lncRNAs were observed to be differ-
entially expressed between the Tm+OVA group and the
Fig. 1 Identification of lncRNAs that were differently expressed as expected based on the lncRNA and mRNA microarray results. a Ovalbumin
(OVA)-induced allergy was established both in vivo and in vitro. b Long noncoding RNAs (lncRNAs) and mRNAs that were differentially expressed
in vivo and in vitro were isolated from the microarray data. c Twenty-three lncRNAs and 96 mRNAs expressed in the same manner (up or down
after the induction of asthma and down or up with the treatment of induced pluripotent stem cell-mesenchymal stem cells (iPSC-MSCs)), both in
vivo and in vitro, were selected. d Target prediction of the 23 lncRNAs was carried out; Pearson’s correlation coefficient with mRNAs involved in
allergy was utilized to screen out 9 of the 23 lncRNAs. Gene ontology and pathway analysis of the co-expressed mRNAs was carried out to
investigate the correlated functions of the genes. PBS phosphate-buffered saline, Tm memory T
Wang et al. Stem Cell Research & Therapy  (2017) 8:2 Page 4 of 14
Tm+OVA+ iPSC-MSC group, with 2217 lncRNAs upregu-
lated and 1958 lncRNAs downregulated (Fig. 3a; p < 0.05
and fold change >2).
The key lncRNA regulators that presented the reverse
variation trends between asthma induction and iPSC-
MSC transplantation should have more significance for
our exploration of the possible mechanisms of MSC-
mediated immunomodulation. Therefore, we next
selected two patterns with opposite directions (up then
down or down then up) after the asthma induction and
after iPSC-MSC treatment for further study (Fig. 3c, d).
However, there were still 109 aberrant lncRNAs for the
pattern of up then down (Fig. 3c) and 104 aberrant
lncRNAs for the pattern of down then up (Fig. 3d). There-
fore, to further narrow the scope of the selected lncRNAs,
we created an overlap for the similar patterns of the differ-
entially expressed lncRNAs in mice and in vitro. One pat-
tern was the overlap of the lncRNAs that increased after
the induction of allergic airway inflammation but de-
creased with the treatment of iPSC-MSCs in mice (up
then down) and the lncRNAs that decreased with the
treatment of iPSC-MSCs in Tm cells in vitro (down)
(Fig. 3c). Another pattern was the overlap of the aberrant
lncRNAs with down then up in mice and the aberrant
lncRNAs that were up in vitro (Fig. 3d). Finally, a total of
23 lncRNAs involved in the immunomodulation of iPSC-
MSCs in allergy were selected. Specifically, 15 lncRNAs
had the pattern of up then down in mice and down in
vitro (Fig. 3c), and 8 lncRNAs had the pattern of down
then up in mice and up in vitro (Fig. 3d). Detailed infor-
mation, including seqname, source database, chromosome
localization, etc, regarding the 23 selected and differen-
tially expressed lncRNAs is shown in Additional file 1:
Table S2. The variation trends for the above 23 lncRNAs
with two different patterns are further clearly shown in
Additional file 1: Figure S2.
Fig. 2 iPSC-MSCs alleviated airway allergy in vivo and reduced Th2 cytokines dramatically in vitro. a Representative photomicrographs of
hematoxylin and eosin (HE)- and periodic acid-Schiff (PAS)-stained lung sections. Original magnification 200×. b The inflammatory infiltration and
goblet cell hyperplasia was quantified by HE and PAS scores (n = 6). c Th2 cytokines IL-4 and IL-13 were detected in the supernatant. Memory T
(Tm) cells were separated from the spleens of the mice and cultured in vitro (n = 5). **p < 0.01. PBS phosphate-buffered saline, IL interleukin, iPSC-
MSC induced pluripotent stem cell-mesenchymal stem cell, OVA ovalbumin
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Fig. 3 lncRNAs and mRNAs that were expressed in the same manner in vivo and in vitro were selected. a A Volcano plot provided the fold-change and
p values of differentially expressed long noncoding RNAs (lncRNAs; top) and mRNAs (bottom). The vertical lines represent a twofold change in expression (up
or down), and the horizontal lines represent p values = 0.05. Pairwise comparisons between the OVA/OVA/PBS group and PBS/PBS/PBS group (left) and
between the OVA/OVA/PBS group and OVA/OVA/iPSC-MSC group (right) are shown. The red points represent differentially expressed lncRNAs or mRNAs with
statistical significance (n=3). b A Volcano plot provided fold-change and p values of differentially expressed lncRNAs (top) and mRNAs (bottom) between the
memory T (Tm) + OVA group and Tm+OVA+ iPSC-MSC group (n= 3). c–f Venn diagrams provided a detailed distribution of differentially expressed lncRNAs
(c, d) and mRNAs (e, f) in two patterns (up then down in vivo and down in vitro (c, e), down then up in vivo and up in vitro (d, f)). The three pies represent
differentially expressed lncRNAs and mRNAs of different combinations between the OVA/OVA/PBS group and PBS/PBS/PBS group (blue), between the OVA/
OVA/iPSC-MSC group and OVA/OVA/PBS group (yellow), and between the Tm+OVA group and Tm+OVA+ iPSC-MSC group (green). The overlap of the
three pies was selected. PBS phosphate-buffered saline, iPSC-MSC induced pluripotent stem cell-mesenchymal stem cell, OVA ovalbumin
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Similarly, we found that a total of 88 mRNAs were dif-
ferentially expressed with a pattern of up then down in
mice and down in vitro (Fig. 3e). Eight mRNAs were dif-
ferentially expressed with a pattern of down then up in
mice and up in vitro (Fig. 3f ).
The pathogenesis of allergic inflammation is a complex
progress associated with various immunocyte dysfunc-
tions, including T lymphocytes, ILCs, DCs, etc. To con-
firm the expression patterns of lncRNAs and mRNAs
associated with allergy and iPSC-MSC immunomodula-
tion comprehensively, hierarchical clustering was per-
formed to analyze the expressions of 213 lncRNAs and
307 mRNAs in vivo. The data showed a distinguishable
lncRNA and mRNA expression profiling pattern between
the OVA/OVA/PBS group and the OVA/OVA/iPSC-MSC
group (Fig. 4). The heat map provided a viable solution for
showing the expression patterns of aberrant lncRNAs and
mRNAs; moreover the hierarchical clustering results were
also helpful for analyzing the interactions and relation-
ships of different RNAs for the subsequent research.
Cis and trans analysis
To predict the potential targets of differentially
expressed lncRNAs involved in allergy and iPSC-MSC
immunomodulation, cis and trans analyses of the se-
lected 23 lncRNAs were performed. A cis-acting analysis
was used to predict the targets of lncRNAs; a major
function of lncRNAs is regulating the neighboring
mRNA expression through cis-acting mechanisms. For
the cis-acting analysis, the genomic position of the se-
lected 23 lncRNAs relative to the genomic positions of
their closest known genes were determined from the
RefSeq and UCSC Known Genes databases [21]. We
searched the genes in the chromosome 10 kb upstream
and downstream of 23 lncRNAs, in which 14 potential
targets were identified. For a trans-acting analysis, we
determined the potential target genes of differentially
expressed lncRNAs with a program known as RNAplex,
which reduced the time needed to localize putative
hybridization sites, mainly by neglecting intramolecular
interactions and using a lightly simplified energy model
[22]. The trans role of 23 selected lncRNAs was exam-
ined with BLAST software and the RNAplex software to
select trans-acting targets, and 44 protein-coding genes
were identified. In total, 58 genes were predicted as
targets of the 23 selected lncRNAs (Additional file 1:
Figure S3A). The results of the target prediction pro-
vided a foundation to research the interaction of
lncRNAs and mRNAs, and some potential target genes
that were predicted may be the key regulators of
lncRNA-mediated allergy regulation and iPSC-MSC
immunomodulation. Therefore, we conducted a GO and
pathway analysis of 58 predicted genes, and all signifi-
cant GO categories and pathways are shown in
Additional file 1: Figure S3B. Most of the predicted
genes were enriched in GO categories, including ras pro-
tein signal transduction, cation binding, and the ncRNA
metabolic process, etc. A KEGG pathway analysis indicated
that the genes were involved in the transforming growth
factor (TGF)-beta signaling pathway and aminoacyl-tRNA
biosynthesis (Additional file 1: Figure S3B).
Co-expression and correlation of lncRNA and mRNA
To further identify the lncRNAs that were closely con-
nected to an immune response, a correlation analysis of
23 selected lncRNAs and mRNAs involved in allergic
inflammation and iPSC-MSC immunomodulation was
carried out. Seventy-two mRNAs, including Il4, Il5, Il13,
Il10, Jak1, Jak3, Stat6, Gata3, Foxp3, Ccl17, and Ccl22
which related to inflammatory cytokines and receptors,
were chosen to confirm their relationships with the 23
selected lncRNAs. Each of the selected lncRNAs was
used to calculate the Pearson’s correlation coefficient
and p value with 72 mRNAs; nine out of 23 lncRNAs
that had more than 40 co-expressed mRNAs were
screened out (Fig. 5a; Pearson’s correlation coefficient
>0.6 or < –0.6, p < 0.05).
The 96 differentially expressed mRNAs in iPSC-MSC
immunomodulation were chosen to confirm their
relationships with the nine screened-out lncRNAs. The
Pearson’s correlation coefficient between the nine
lncRNAs and 96 mRNAs was also calculated (Pearson’s
correlation coefficient >0.6 or < –0.6, p value <0.05).
These lncRNAs had a co-expression with most of the 96
mRNAs; a pattern of high numbers of connections
between protein-coding mRNAs and lncRNAs is also
observed in a visual solution (Fig. 5b). We found that
these nine lncRNAs were co-expressed with 74 protein-
coding mRNAs, including Il4, Il10, Il1α, Il1β, Ccl2, Ccl4,
Ccl9, Ccl22, and CD14, which were associated with the
immune response. Moreover, these nine lncRNAs may
participate in airway allergic inflammation and iPSC-
MSC immunomodulation through these mRNAs.
Gene ontology and pathway analysis of mRNA expression
To investigate whether the clustering of genes correlated
with specific functions and pathways, we performed a
GO and pathway analysis of the differentially expressed
mRNAs which were co-expressed with the nine
screened-out lncRNAs. The GO and KEGG analyses of
these mRNAs revealed that major enriched pathways
were associated with immune responses, cytokine
activity, cytokine-cytokine receptor interactions, and
chemokine signaling pathways. The ontologies covered
three domains: BP, CC, and MF; the top five significant
GO categories and pathways are shown in Fig. 5c. We
found that the most enriched BP ontologies targeted by
lncRNAs that co-expressed mRNAs were the immune
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response, immune system process, defense response,
inflammatory response, and leukocyte chemotaxis. The
most enriched CC ontologies were the extracellular
space, extracellular region, extracellular region part, cell
surface, and the external side of the plasma membrane.
The most enriched MF ontologies were cytokine activity,
cytokine receptor binding, chemokine activity,
chemokine receptor binding, and receptor binding. The
KEGG pathway analysis indicated that the lncRNA co-
expressed mRNAs were involved in cytokine-cytokine
receptor interactions, chemokine signaling pathways,
malaria, pertussis, and rheumatoid arthritis. The results
of the GO and KEGG pathway analysis suggested that
lncRNAs may be associated with an immune response.
Fig. 4 The differentially expressed lncRNAs associated with allergy and iPSC-MSC treatment. Hierarchical cluster analysis of aberrant lncRNAs (a) and
mRNAs (b) whose expressions were changed in OVA/OVA/PBS and restored in OVA/OVA/iPSC-MSC (n = 3 for each group). Red indicates high relative
expression and green indicates low relative expression. PBS phosphate-buffered saline, iPSC-MSC induced pluripotent stem cell-mesenchymal stem cell,
OVA ovalbumin
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Fig. 5 (See legend on next page.)
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Quantitative real-time-PCR
To confirm the highest correlative lncRNAs with airway
allergic inflammation and iPSC-MSC immunomodulation,
qRT-PCR was used to validate the nine screened-out
lncRNAs by utilizing lung samples from the PBS/PBS/
PBS, OVA/OVA/PBS, and OVA/OVA/iPSC-MSC groups
(Fig. 6). Two lncRNAs, MM9LINCRNAEXON12105+ and
AK089315, were identified because their expressions were
the best in terms of conformance and stability, similar to
those obtained from the microarray analysis. The above
two lncRNAs showed significant differences in three
groups in vivo, which were upregulated in asthma and
downregulated in the iPSC-MSC treatment. Furthermore,
two other lncRNAs, ENSMUST00000124434 and
(See figure on previous page.)
Fig. 5 The nine lncRNAs were co-expressed with mRNAs, which were enriched in the immune response. a Pearson’s correlation coefficient of 72 mRNAs
(vertical axis) involved in inflammatory cytokines and receptors, together with 23 screened-out lncRNAs was taken. Nine lncRNAs (horizontal axis) were isolated,
in which >40 co-expressed mRNAs were selected. Pearson’s correlation coefficients >0.6 or < –0.6, and p values <0.05 were considered correlative. Red
represents a co-expressed pair, and white does not. b The co-expression network was established between the selected nine lncRNAs and 96 mRNAs. The
red nodes denote lncRNAs, and the green nodes denote mRNAs. Pearson’s correlation coefficients >0.6 or < –0.6, and p values <0.05 were considered
correlative. c GO and pathway analyses of 96 mRNAs co-expressed with lncRNAs were performed. The ontology covers three domains: biological process,
cellular component, and molecular function. The top five significant GO categories and pathways are shown
Fig. 6 Eight selected lncRNA expression levels were validated in vivo. The expressions of the selected eight lncRNAs were validated by qRT-PCR
in three groups in vivo. Two lncRNAs, MM9LINCRNAEXON12105+ and AK089315, were upregulated in the allergy reaction and downregulated in
iPSC-MSC immunomodulation in vivo. n = 6, 7, and 6; *p < 0.05, **p < 0.01. PBS phosphate-buffered saline, iPSC-MSC induced pluripotent stem cell-
mesenchymal stem cell, OVA ovalbumin
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AK029213, showed trends as expected, which were down-
regulated after asthma induction and upregulated after
iPSC-MSC treatment, but the results were not statistically
significant, probably because of the limited sample size.
The results indicated that MM9LINCRNAEXON12105+
and AK089315 may be the potential regulators of allergy
and the targets of iPSC-MSC immunomodulation (the
primer specificity of one lncRNA,mouselincRNA0307+,
was not high enough, so only eight are shown in Fig. 6).
Discussion
Adult MSCs, including BM-MSCs, exhibit several inher-
ent defects that hinder their regenerative efficiency for
standard clinical applications, such as a limited prolifera-
tive capacity and rapid loss of differentiation potential
[23]. Moreover, MSCs present high batch-to-batch vari-
ability due to differences in donor age, health conditions,
and genetic background [24]. iPSC-MSCs not only show
much greater proliferation and differentiation capacity
but also have low immunogenicity compared to BM-
MSCs [25], which overcomes the disadvantages of adult
MSCs. Therefore, iPSC-MSCs that have broader pros-
pects in medical application were used in our research.
In this study, the expression profiles of mRNAs and
lncRNAs in asthma induction and iPSC-MSC treatment
were examined via microarray, in which 23 lncRNAs
and 96 mRNAs were identified as being differentially
expressed in the same manner between in vivo and in
vitro. Fifty-eight protein-coding genes were predicted as
potential targets of the 23 lncRNAs. Nine out of 23
lncRNAs were selected via a correlation analysis, with 72
protein-coding genes involved in inflammatory cytokines
and receptors. A correlation analysis confirmed the rela-
tionships between the nine selected lncRNAs and the 96
differentially expressed mRNAs, most of which were
enriched in the immune process. Finally, lncRNAs
MM9LINCRNAEXON12105+ and AK089315 were em-
phasized via qRT-PCR validation. These lncRNAs may
be the potential targets of allergic reactions and MSC-
mediated immunomodulation.
lncRNAs have been proven to play crucial roles in di-
verse processes and diseases via regulating protein-coding
gene expressions [8]. For instance, the famous lncRNA
MALAT1 was proven to indicate a hint of tumor metasta-
sis [26]. In recent years, some evidence has been found to
show that lncRNAs are important regulators of the im-
mune response [27]. They were not only involved in the
innate immune response but also participated in T-cell
regulation and host-pathogen interactions [28–30]. Xia et
al. [10] found that the expression profiles of lncRNAs in
different stages of CD4+ T cells are distinguishable. It was
demonstrated that changes in lncRNA expression were as-
sociated with severe asthma in circulating CD8+ T cells
[11]. The lncRNA BANCR was upregulated in
eosinophilic esophagitis, which is another allergic inflam-
matory disorder, and was induced in IL-13 that treated
primary esophageal epithelial cells [12]. However, lncRNA
profiles in asthma which are dominant in terms of Th2 re-
sponses, remain unclear. Using the lncRNA microarray,
we identified that 1340 lncRNAs were differentially
expressed after the induction of asthma, with 666
lncRNAs being upregulated and 674 lncRNAs downregu-
lated. Using a series of bioinformatics technologies, we
further studied the possible nine lncRNAs co-expressed
with the most differentially expressed mRNAs enriched in
the immune response. We finally confirmed using qRT-
PCR that the lncRNAs MM9LINCRNAEXON12105+ and
AK089315 increased after the induction of asthma. We ac-
knowledge that there should be more lncRNAs involved
in the allergic airway inflammation aside from the
lncRNAs selected for the overlap with the treatment of
iPSC-MSCs in our study. Our study provides clear evi-
dence that there are different lncRNA expressions for
asthma, especially for T cells, suggesting their potential
role in the immunopathogenesis and therapy of these
diseases.
We previously reported that iPSC-MSCs significantly
prevent allergy airway inflammation and regulate the T-
lymphocyte responses in allergic rhinitis [17]. Some
studies reported that lncRNAs played a role in the main-
tenance and differentiation of MSCs for mature lineages
[31], and one report described lncRNA expression
patterns in TLR3 that was stimulated in adipose tissue-
derived MSCs [18]. However, previous studies focused
on the lncRNA profiles in MSCs but not on the targets
of MSCs. There are no reports on the lncRNA expres-
sion profiles after the treatment of MSCs, even for BM-
MSCs on immune cells or in immune/allergic diseases.
In this study, we identified that 846 or 4176 lncRNAs
were differentially expressed after the iPSC-MSC treat-
ment in mice or in the in vitro model, respectively. After
a series of analyses, nine lncRNAs co-expressed with the
most differentially expressed mRNAs enriched in the
immune response were screened out, and the lncRNAs
MM9LINCRNAEXON12105+ and AK089315 were fi-
nally confirmed by qRT-PCR to increase with the iPSC-
MSC treatment. We believe that our study is the first re-
port that links lncRNAs with MSCs, especially iPSC-
MSC immunomodulatory properties.
Our microarray analysis identified that a total of 213
lncRNAs were differentially expressed in opposite direc-
tions (down then up or up then down) after the asthma
induction and after iPSC-MSC treatment. However, the
number of candidate lncRNAs was still too large. An in
vitro study was supplemented to narrow the scope. IL-4
and IL-13, but not IL-5, were highly secreted by the sen-
sitized Tm cells after challenges in the culture. These re-
sults prove that we utilized a proper in vitro model for
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allergy research. Moreover, for the first time ever, we
demonstrated that iPSC-MSCs dramatically decreased
the levels of IL-4 and IL-13 in an ex vivo condition. To
identify lncRNAs associated with the allergy reaction
and iPSC-MSC immunomodulation, two types of micro-
array patterns were selected. One was upregulated after
the induction of allergic airway inflammation, downregu-
lated with the treatment of iPSC-MSCs in mice, and
downregulated with the treatment of iPSC-MSCs in Tm
cells in vitro (up then down in mice and down in vitro).
Another was completely the opposite (down then up in
mice and up in vitro). Twenty-three lncRNAs were
screened out via the overlap of the in vivo study and in
vitro study. Furthermore, nine out of 23 lncRNAs were
identified as being involved in the immune response after
the analysis of the target prediction, GO, and pathway
analysis, and Pearson’s correlation coefficient.
We also carried out an mRNA microarray at the same
time. mRNAs involved in allergy and iPSC-MSC treat-
ment were also identified, and their relationships with
the lncRNAs were analyzed. Among the 72 mRNAs co-
expressed with the selected 23 lncRNAs, some were
closely associated with allergic inflammation, such as:
Th2 cytokine coding genes, including Il4, Il5, and Il13
[32]; Th2-specific transcription factors, including Stat5
and Stat6 [33]; Treg transcription factors, including
Foxp3 [34]; and chemokine coding genes such as Ccl17
and Ccl22, which play a critical role in the recruitment
and activation of Th2 cells [35]. The protein-coding
genes listed were closely linked to allergy and associated
with lncRNAs; moreover, some of them such as Il4, Il5,
and Il13 were regulated by iPSC-MSC treatment [16],
and therefore these lncRNAs were also associated with
iPSC-MSC immunomodulation. Our data confirm that
lncRNAs are involved in asthma inflammation in mice,
and they are also involved in the immunomodulation
process when treated by iPSC-MSCs.
Despite accumulating evidence suggesting that the ma-
jority of lncRNAs are likely to be functional [36, 37], we
also identified more than 200 lncRNAs that were involved
in iPSC-MSC immunomodulation. However, only nine
lncRNAs have been shown to be relevant. Finally, by using
additional lung samples, two lncRNAs, MM9LINCR-
NAEXON12105+ and AK089315, were proven to be the
most relevant because they differentially expressed signifi-
cant differences in the airway allergy and iPSC-MSC treat-
ment. For further functional study, genomic modifications
of the above two selected lncRNAs could be used to ex-
plore their functions in identified mRNA regulation. The
targeted lncRNA knockout or overexpressed T cells that
were challenged and co-cultured with iPSC-MSCs in vitro
could be processed with a microarray or via RNA-seq ana-
lysis to verify that the mRNAs are regulated by a specific
lncRNA. The results matched the identified mRNAs
associated with allergy, and iPSC-MSC treatment should be
selected. The mRNAs mediated by two selected lncRNAs
would be determined, and the lncRNA/mRNA pathway in-
volved in the allergic reaction and iPSC-MSC immunoregu-
lation could be verified. We have attempted to perform
genomic modification of the two target lncRNAs in murine
primary Tm cells with small-interfering RNA. However, pri-
mary T lymphocytes are generally resistant to non-viral
vector-based transfection methods [38]. Significant time and
effort is still needed to solve this problem. This part of the
work will need to be completed in the future.
In our study, the in vitro study was supplemented to
help narrow the scope of lncRNAs selected from the in
vivo data. The advantage of this was effective in focusing
on the target lncRNAs. However, the limitation was that
the samples between the in vivo and in vitro study were
different. The lungs used for the in vivo study not only
contained T lymphocytes, which were used for the in
vitro study, but also included other types of cells such as
epithelial cells, ILC2, and DCs. Therefore, the selected
lncRNAs in this study still focused on T lymphocytes.
The selected lncRNAs involved in the allergy and iPSC-
MSC immunomodulation may also be associated with
other types of cells, such as epithelial cells and DCs.
Moreover, MSCs were also shown to regulate epithelial
cells, DCs, etc. [39, 40], which is a research emphasis for
the future.
Conclusions
In conclusion, our study found that airway allergic inflam-
mation can cause alterations of lncRNAs expressed in mice,
and some of these altered lncRNAs are also involved in the
alleviation of iPSC-MSC airway inflammation. This study
evaluated the aberrant lncRNA expression profiles both in
asthma and iPSC-MSC treatment, which demonstrated that
lncRNAs may be related to allergy and iPSC-MSC immuno-
modulation. This study provides a key foundation to study
the mechanisms underlying airway allergic inflammation
and iPSC-MSC immunomodulation, which may be helpful
in promoting iPSC-MSC medical applications.
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